A phase I study to demonstrate the safety and tolerability of oral MNX-200 in metastatic or locally advanced pediatric cancer.
Latest Information Update: 06 Jan 2016
At a glance
- Drugs MNX 200 (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Jan 2016 New trial record